Valuation: NovoCure Limited

Market Cap 2.32B 2.04B 1.89B 1.74B 3.26B 224B 3.32B 22.62B 8.82B 109B 8.69B 8.5B 379B P/E 2026 *
-14.6x
P/E 2027 * -20.6x
Enterprise Value 2.12B 1.86B 1.73B 1.59B 2.99B 205B 3.04B 20.72B 8.08B 100B 7.96B 7.79B 347B EV / Sales 2026 *
2.95x
EV / Sales 2027 * 2.52x
Free-Float
89.99%
Yield 2026 *
-
Yield 2027 * -
1 day+28.39%
1 week+21.74%
Current month+31.95%
1 month+41.47%
3 months+58.78%
6 months+48.62%
Current year+54.60%
1 week 15.2
Extreme 15.2
20.55
1 month 14.63
Extreme 14.63
20.55
Current year 9.82
Extreme 9.82
20.55
1 year 9.82
Extreme 9.82
20.55
3 years 9.82
Extreme 9.82
41.51
5 years 9.82
Extreme 9.82
188.94
10 years 5.95
Extreme 5.95
232.76
Manager TitleAgeSince
Chief Executive Officer 46 30/11/2025
Director of Finance/CFO 52 31/12/2024
Chief Tech/Sci/R&D Officer - 16/01/2023
Director TitleAgeSince
Director/Board Member 59 31/12/2011
Chairman 63 31/12/2008
Director/Board Member 64 04/08/2011
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Free

Chief Executive Officer

1,905 0.0016%
30/06/26 Free

General Counsel

1,299 0.0011%
30/06/26 Free

Director

268 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+28.39%+21.74%+21.08%-48.64% 2.32B
+0.44%-0.53%+36.21%+4.72% 12.5B
-1.76%+8.53%+18.21%+19.35% 6.39B
-0.50%-4.96%+43.21%+19.54% 5.5B
0.00%+2.83% - - 4.59B
+2.14%+2.27%-26.98%+22.99% 4.47B
-1.76%-1.65%-21.73%-21.97% 4.03B
0.00%-7.09%-17.02%+219.26% 1.71B
-0.16%-0.16%+55.52%-3.18% 1.55B
+0.05%-8.98%-23.73%-52.96% 1.22B
Average +2.72%+2.45%+9.42%+17.68% 4.43B
Weighted average by Cap. +1.39%+2.42%+17.00%+12.53%

Financials

2026 *2027 *
Net sales 720M 633M 588M 541M 1.01B 69.72B 1.03B 7.03B 2.74B 34.01B 2.7B 2.64B 118B 792M 696M 647M 595M 1.12B 76.66B 1.14B 7.73B 3.02B 37.39B 2.97B 2.91B 130B
Net income -157M -138M -128M -118M -221M -15.16B -225M -1.53B -597M -7.39B -588M -575M -25.65B -106M -93.07M -86.46M -79.52M -149M -10.25B -152M -1.03B -403M -5B -397M -389M -17.34B
Net Debt -195M -172M -159M -147M -275M -18.89B -280M -1.91B -743M -9.21B -732M -716M -31.96B -317M -279M -259M -238M -447M -30.72B -455M -3.1B -1.21B -14.98B -1.19B -1.16B -51.98B
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
23/07/26 US$19.99 +28.39% 8,948,689
22/07/26 US$15.57 -2.69% 1,064,781
21/07/26 US$16.00 +0.38% 1,069,311
20/07/26 US$15.94 +0.13% 933,512
17/07/26 US$15.92 -3.05% 856,319
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
19.99USD
Average target price
25.71USD
Spread / Average Target
+28.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVCR Stock